Pathogenesis and treatment of Sjogren's syndrome: review and update

Q Zhan, J Zhang, Y Lin, W Chen, X Fan… - Frontiers in …, 2023 - frontiersin.org
Sjogren's syndrome (SS) is a chronic autoimmune disease accompanied by multiple
lesions. The main manifestations include dryness of the mouth and eyes, along with …

Current state of knowledge on primary Sjögren's syndrome, an autoimmune exocrinopathy

D Parisis, C Chivasso, J Perret, MS Soyfoo… - Journal of clinical …, 2020 - mdpi.com
Primary Sjögren's syndrome (pSS) is a chronic systemic autoimmune rheumatic disease
characterized by lymphoplasmacytic infiltration of the salivary and lacrimal glands, whereby …

One year in review 2020: comorbidities, diagnosis and treatment of primary Sjogren's syndrome

V Manfrè, G Cafaro, I Riccucci, A Zabotti… - Clinical and …, 2021 - research.rug.nl
Primary Sjogren's syndrome (pSS) is a complex and heterogeneous disorder characterised
by a wide spectrum of glandular and extra-glandular features. The discovery of novel …

[PDF][PDF] One year in review 2020: pathogenesis of primary Sjögren's syndrome

M Bombardieri, OD Argyropoulou, F Ferro… - Clin Exp …, 2020 - clinexprheumatol.org
The pathogenesis of primary Sjögren's syndrome (pSS) remains poorly understood.
However, important efforts have been made during the last few months. In this review …

Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sjögren's syndrome: a randomized, phase 2, double-blind, placebo-controlled study

E Price, M Bombardieri, A Kivitz, F Matzkies… - …, 2022 - academic.oup.com
Objective The aim of this study was to characterize the safety and efficacy of filgotinib,
lanraplenib and tirabrutinib in patients with active SS. Methods This multicentre, double …

Premature stroke and cardiovascular risk in primary Sjögren's syndrome

CL Zippel, S Beider, E Kramer, FF Konen… - Frontiers in …, 2022 - frontiersin.org
Introduction Primary Sjögren's syndrome (pSS) is associated with an increased prevalence
of traditional risk factors and cardiovascular diseases (CVDs). The study aimed to identify …

[HTML][HTML] Long-term abatacept treatment for 48 weeks in patients with primary sjögren's syndrome: The open-label extension phase of the ASAP-III trial

L de Wolff, JF van Nimwegen, E Mossel… - Seminars in Arthritis and …, 2022 - Elsevier
Objective To investigate treatment efficacy of long-term abatacept treatment in pSS patients.
Methods The single-centre ASAP-III trial consisted of two phases: the randomised, double …

Defining the role of monocytes in Sjögren's syndrome

JM Sequí-Sabater, L Beretta - International Journal of Molecular Sciences, 2022 - mdpi.com
Sjögren's syndrome is one of the most prevalent autoimmune diseases after rheumatoid
arthritis, with a preference for middle age, and is characterised by exocrine glandular …

Ten years of the ESSDAI: is it fit for purpose?

L de Wolff, S Arends, JF van Nimwegen… - Clinical and …, 2020 - research.rug.nl
Primary Sjögren's syndrome (pSS) is a very heterogeneous disease with systemic
manifestations such as arthritis, skin, lung and renal involvement. To be able to assess …

IgG4-related disease: mimickers and diagnostic pitfalls

E Martín-Nares, G Hernández-Molina… - JCR: Journal of …, 2022 - journals.lww.com
Background The tendency of IgG4-related disease (IgG4-RD) to form pseudotumors, as well
as its multisystemic nature, makes it the perfect mimicker of many conditions. Moreover …